Share >  
Share
Share on Tumblr

Hari Om Bhatia

News »

   latest by relevance
Looking at inorganic growth opportunities: Surya Pharma
Mar 22, 2011 at 15:38 | Source: CNBC-TV18
In an interview with CNBC-TV18, Hari Om Bhatia, president finance, Surya Pharmaceutical, spoke about the latest happenings in his company and sector.
ActivOn to contribute USD 20mn in FY11: Surya Pharma
Dec 28, 2010 at 13:10 | Source: CNBC-TV18
With the acquisition of Ameshire Investment Corp, USA, Surya Pharmaceuticals has acquired the over the counter (OTC) brand ActivOn. Hari Om Bhatia of Surya Pharma, in an exclusive interview with CNBC-TV18 shares the details of the purchase.
अमेरिका में एक्टिवऑन ब्रांड खरीदाः सूर्या फार्मा
Dec 28, 2010 at 11:35 | Source:
सूर्या फार्मा ने एक्टिवऑन को बेचने वाली मार्केटिंग कंपनी को इस सौदे के तहत खरीदा है।
Surya Pharma eyes more fund raising via FCCB's in 6 months
Oct 13, 2010 at 16:17 | Source: CNBC-TV18
Surya Pharma successfully concluded their USD 25 million global depository receipt (GDR) issue today. The company aims to utilize the funds for their formulation division, their subsidiaries within India and overseas as well as a few greenfield projects, said the president of finance Hari Om Bhatia in an exclusive interview with CNBC-TV18.
Looking to acquire cos in formulations space: Surya Pharma
Aug 20, 2010 at 16:27 | Source: CNBC-TV18
In an interview with CNBC-TV18, Hari Om Bhatia, President-Finance of Surya Pharmaceutical said, During the year the growth which we have seen in the company is because of various expansion plans and certain additions to the activities which have resulted into this.
High raw material, int cost effect bottomline: Surya Pharma
Nov 04, 2009 at 13:37 | Source: CNBC-TV18
In an interview with CNBC-TV18, Hari Om Bhatia, President of Finance, Surya Pharma spoke about the results and his outlook for the company.

Videos »
Looking at inorganic growth opportunities: Surya Pharma
ActivOn to contribute USD 20mn in FY11: Surya Pharma
Surya Pharma eyes more fund raising via FCCB's in 6 months
Looking to acquire cos in formulations space: Surya Pharma
High raw material, int cost effect bottomline: Surya Pharma
more »

Photos »

  /  

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window